热门资讯> 正文
FDA修改激素失调治疗拒绝信，取消审查
2026-01-30 22:19
- Corcept Therapeutics (CORT) lost ~16% in the premarket on Friday after the FDA revised a Complete Response Letter issued last month in connection with the company’s marketing application for its hormonal disorder therapy relacorilant.
- The agency declined to approve the New Drug Application filed by the Redwood City, California-based pharma, noting it could not determine a favorable benefit-risk assessment for the drug without additional data, according to a company press release in December.
- The NDA was aimed at seeking U.S. approval of relacorilant for patients with high blood pressure related to a hormonal disorder called hypercortisolism (Cushing's syndrome).
- In the partially redacted letter dated Jan. 28, the FDA noted that while the prior CRL contained no errors, it “is being updated to respond to Corcept’s communication.”
More on Corcept Therapeutics
- Why Corcept Therapeutics' Relacorilant Fell Short And What It Means For The Company
- Corcept: Korlym Defies Generics As Relacorilant Hits An FDA CRL (Rating Upgrade)
- Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug
- Corcept climbs as ovarian cancer therapy succeeds in late-stage trial
- Corcept sinks as FDA rejects hormonal disorder therapy
推荐文章
港股周报 | 中国大模型“春节档”打响！智谱周涨超138%；巨亏超230亿！美团周内重挫超10%
一周财经日历 | 港美股迎“春节+总统日”双假期！万亿零售巨头沃尔玛将发财报
一周IPO | 赚钱效应持续火热！年内24只上市新股“0”破发；“图模融合第一股”海致科技首日飙涨逾242%
从软件到房地产，美国多板块陷入AI恐慌抛售潮
Meta计划为智能眼镜添加人脸识别技术
危机四伏，市场却似乎毫不在意
美股机会日报 | 降息预期升温！美国1月CPI年率创去年5月来新低；净利、指引双超预期！应用材料盘前涨超10%
财报前瞻 | 英伟达Q4财报放榜在即！高盛、瑞银预计将大超预期，两大关键催化将带来意外惊喜？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
